Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial

被引：0
|
作者：
Olson, R. A. [1 ,2 ]
Jiang, W. [1 ,2 ]
Liu, M. C. [1 ,3 ]
Bergman, A. [3 ]
Schellenberg, D. [1 ,4 ]
Mou, B. [1 ,5 ]
Alexander, A. S. [1 ,6 ]
Carolan, H. [1 ,3 ]
Hsu, F. [1 ,7 ]
Miller, S. [1 ,2 ]
Atrchian, S. [8 ]
Chan, E. K. [1 ,3 ]
Ho, C. [1 ,9 ]
Mohamed, I. G. [1 ,5 ]
Lin, A. [1 ,5 ]
Berrang, T. [1 ,6 ]
Bang, A. [1 ,3 ]
Chng, N. [2 ]
Matthews, Q. [2 ]
Huang, V. [4 ]
Mestrovic, T. [6 ]
Hyde, D.
Lund, C. R. [1 ,4 ]
Pai, H. H. [1 ,6 ]
Valev, B. [1 ,6 ]
Lefresne, S. [10 ,11 ]
Tyldesley, S. [1 ,3 ]
机构：
[1] Univ British Columbia, Vancouver, BC, Canada
[2] BC Canc Prince George, Prince George, BC, Canada
[3] BC Canc Vancouver, Vancouver, BC, Canada
[4] BC Canc Surrey, Surrey, BC, Canada
[5] BC Canc Kelowna, Kelowna, BC, Canada
[6] BC Canc Victoria, Victoria, BC, Canada
[7] BC Canc Abbotsford, Abbotsford, BC, Canada
[8] BC Canc Agcy, Radiat Oncol, Kelowna, BC, Canada
[9] BC Canc Fraser Valley, Surrey, BC, Canada
[10] BC Canc Agcy, Vancouver, BC, Canada
[11] Univ British Columbia, Dept Surg, Div Radiat Oncol, Vancouver, BC, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [41] STEREOTACTIC ABLATIVE RADIOTHERAPY FOR THE COMPREHENSIVE TREATMENT OF OLIGOMETASTATIC CANCERS: LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL
    Palma, David
    Olson, Robert
    Harrow, Stephen
    Gaede, Stewart
    Louie, Alexander
    Haasbeek, Cornelis
    Mulroy, Liam
    Lock, Michael
    Rodrigues, George
    Yaremko, Brian
    Ahmad, Belal
    Schlijper, Roel
    Laba, Joanna
    Qu, Melody
    Schellenberg, Devin
    Senthi, Sashendra
    Swaminath, Anand
    Kopek, Neil
    Liu, Mitchell
    Moore, Karen
    Currie, Suzanne
    Bauman, Glenn
    Warner, Andrew
    Senan, Suresh
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S7 - S7
  • [42] First results of the first cohort of a phase I dose-escalation trial on SABR for oligometastases
    Mercier, C.
    Dirix, P.
    Billiet, C.
    Meijnders, P.
    Vermeulen, P.
    Rypens, C.
    Huget, P.
    Verellen, D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S873 - S874
  • [43] Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
    Cole, Suzanne
    Kim, Se Eun
    Wentland, Andrew
    Lin, Mu-Han
    Kapur, Payal
    Wulff-Burchfield, Elizabeth Marie
    Shevrin, Daniel
    Gurley, Tami
    Lin, John C.
    Wagner, Lynne I.
    McKay, Rana R.
    Brugarolas, James
    Qin, Qian
    Gunter, Tyler
    Kyriakopoulos, Christos
    Harichand-Herdt, Seema
    Sykes, Glenn
    Haas, Naomi Balzer
    Carducci, Michael A.
    Hannan, Raquibul
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS615 - TPS615
  • [44] Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
    Kim, Se Eun
    Cole, Suzanne
    Wulff-Burchfield, Elizabeth Marie
    Wentland, Andrew
    Hannan, Mu-Han
    Kapur, Payal
    Shevrin, Daniel
    Gurley, Tami
    Lin, John Kent
    Brugarolas, James
    Timmerman, Robert D.
    Mckay, Rana R.
    Wagner, Lynne I.
    Haas, Naomi B.
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS489 - TPS489
  • [45] Phase II Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) in Surgically Operable Stage I Non-Small Cell Lung Cancer (STARS)
    Chang, Joe Y.
    Mehran, Reza
    Balter, Peter
    Mcrae, Stephen
    Feng, Lei
    Berry, Donald
    Komaki, Ritsuko U.
    Roth, Jack
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S563 - S563
  • [46] A Phase 1 Trial of Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Cancer: Toxicity and Quality of Life
    Erler, D.
    Cheung, P.
    Sahgal, A.
    Chung, H. T.
    Poon, I.
    Chu, W.
    Zhang, L.
    Bedard, G.
    Pulenzas, N.
    Chow, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E492 - E492
  • [47] QUALITY OF LIFE OUTCOMES AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) VERSUS STANDARD OF CARE PALLIATIVE TREATMENTS: A SECONDARY ANALYSIS OF THE SABR-COMET RANDOMIZED TRIAL
    Olson, Robert
    Senan, Suresh
    Harrow, Stephen
    Gaede, Stewart
    Louie, Alexander
    Haasbeek, Niels
    Mulroy, Liam
    Lock, Michael
    Rodriques, George
    Yaremko, Brian
    Schellenberg, Devin
    Ahmad, Belal
    Griffioen, Gwendolyn
    Senthi, Sashendra
    Swaminath, Anand
    Kopek, Neil
    Liu, Mitchell
    Moore, Karen
    Currie, Suzanne
    Bauman, Glenn
    Warner, Andrew
    Palma, David
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S41 - S41
  • [48] Ultra-hypofractionated SABR in High risk prostate cancer: preliminary results of a phase II trial
    Montero, A.
    Rossi, K.
    Hernando, O.
    Lopez, M.
    Valero, J.
    Canadillas, C.
    Chen-Zhao, X.
    Ciervide, R.
    Garcia-Aranda, M.
    Alvarez, B.
    Prado, A.
    Alonso, R.
    Sanchez, E.
    Izquierdo, M.
    Fernandez-Leton, P.
    Rubio, C.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1194 - S1195
  • [49] Phase I Dose-Escalation Trial of Stereotactic Ablative Body Radiotherapy (SAbR) for Men with High-Risk Prostate Cancer
    Salamekh, S.
    Desai, N. B.
    Folkert, M. R.
    Garant, A.
    Mannala, S.
    Mohamad, O.
    Choy, H.
    Roehrborn, C.
    Lotan, Y.
    Timmerman, R. D.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E869 - E869
  • [50] A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial)
    David, Steven
    Savas, Peter
    Siva, Shankar
    White, Michelle
    Neeson, Michael W.
    White, Shane
    Marx, Gavin
    Cheuk, Robyn
    Grogan, Michelle
    Farrell, Maria
    Foudoulis, Jessica
    Dempsey, Annette
    Neeson, Paul J.
    Bressel, Mathias
    Loi, Sherene
    CANCER RESEARCH, 2022, 82 (04)
12345